Tests completed for heparin products on the Danish market

Pfizer has now tested the remaining nine Fragmin® batches which the Danish Medicines Agency instructed Pfizer to withdraw from the market yesterday.

The impurity oversulfated chondroitin sulfate (OSCS) has not been found in any of the batches, and the Danish Medicines Agency has therefore lifted its withdrawal requirement accordingly.

You can read our previous heparin announcements in the factbox to the right.

For further information, please contact Anne-Marie Vangsted, Inspection, Laboratories & Enforcement, telephone +45 4488 9315.

Danish Medicines Agency, 25 April 2008